MedPath

Oral Tramadol Versus Oral Dexketoprofen for Reducing Pain During Office Hysteroscopy

Phase 3
Conditions
Hysteroscopy
Interventions
Registration Number
NCT03585036
Lead Sponsor
Cairo University
Brief Summary

Two hundreds and twenty five postmenopausal women undergoing outpatient hysteroscopy and endometrial biopsy will be randomly divided into three equal groups. To ensure blinding the investigators will use the double dummy technique in which group 1 will receive Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) orally in addition to a placebo similar to Celecoxib, group 2 will receive dexketoprofen 25mg (neo ketadex 25, Marcryl, Egypt) in addition to a placebo similar to Tramadol, and group 3 will received a placebo similar to Tramadol and a placebo similar to Celecoxib. All drugs will be given 2 hours before the procedure. An independent person will generate the allocation sequence using computer generated random numbers.

Detailed Description

Two hundreds and twenty five postmenopausal women undergoing outpatient hysteroscopy and endometrial biopsy will be randomly divided into three equal groups. To ensure blinding the investigators will use the double dummy technique in which group 1 will receive Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) orally in addition to a placebo similar to Celecoxib, group 2 will receive dexketoprofen 25mg (neo ketadex 25, Marcryl, Egypt) in addition to a placebo similar to Tramadol, and group 3 will received a placebo similar to Tramadol and a placebo similar to Celecoxib. All drugs will be given 2 hours before the procedure. An independent person will generate the allocation sequence using computer generated random numbers.

Statistics:

Quantitative data will be statistically represented in terms of mean ± standard deviation (± SD) while categorical data will be represented as frequency and percentage. Comparison of quantitative data will be done using ANOVA test for independent samples while categorical data will be compared using Chi squared test or Fisher exact test when appropriate. A probability value (p value) less than 0.05 will be considered significant.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
210
Inclusion Criteria
  • Post menopausal women.
  • vaginal bleeding.
  • Endometrial thickness >4mm.
Exclusion Criteria
  • Medical disorders like uncontrolled diabetes or hypertension, cardiac, renal, liver disease.
  • Gastritis or peptic ulcer.
  • Allergy to Tramadol or dexketoprofen.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
placeboPlaceboDrug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure. Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure
dexketoprofendexketoprofenDrug: dexketoprofen Women will receive oral dexketoprofen 25mg 2 hours before the procedure Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.
tramadolTramadolDrug: Tramadol Women will receive oral Tramadol 100 mg 2 hours before the procedure Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure .
Primary Outcome Measures
NameTimeMethod
Patient's perception of pain during the procedure2 minutes after starting the procedure

The nurse will hand the patient a VAS and the patient will mark the point corresponding to her pain.VAS of 0 indicates no pain and VAS of 10 indicates the worst possible experienced pain

Secondary Outcome Measures
NameTimeMethod
Pain after the procedure30 minutes after completing the procedure

The nurse will hand the patient a VAS and the patient will mark the point corresponding to her pain.

© Copyright 2025. All Rights Reserved by MedPath